Crossmark

Osteopontin improves sensitivity to tyrosine kinase inhibitor in lung adenocarcinoma in vitro by promoting epidermal growth factor receptor phosphorylation

Crossref DOI link: https://doi.org/10.1007/s00432-021-03731-2

Published Online: 2021-07-13

Published Print: 2021-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wang, Yu-Jin

Wang, Qing-Wen

Yu, Dong-Hu

Song, Cong-Kuan

Guo, Zi-Xin

Liu, Xiao-Ping

Chen, Chen

Yao, Jie

Wang, Ai-Fen

Hu, Wei-Dong https://orcid.org/0000-0003-3646-8572
License Information

Text and Data Mining valid from 2021-07-13

Version of Record valid from 2021-07-13
More Information

Article History

Received: 23 February 2021

Accepted: 6 July 2021

First Online: 13 July 2021

Declarations

:

: The authors declare no conflict of interest.

: Informed consents were obtained from all subject, and this study was approved by the Ethics Committee of Zhongnan Hospital of Wuhan University.

Document is current

Any future updates will be listed below